Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BREAKFAST: FMD and Metformin in TNBC
NCT04248998Phase 2Unknown
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- May 2020
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of metformin in triple-negative breast cancer (TNBC), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Pathological Complete Response rate at 36 months. Status: unknown.
02
Drugs
metformin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04248998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04248998.